Akebia

Jun 18, 2020

Akebia Therapeutics Announces New Chief Financial Officer

May 26, 2020

Akebia Therapeutics to Present at Jefferies Virtual Global Healthcare Conference

May 21, 2020

Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders

May 19, 2020

Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

May 18, 2020

Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan

May 11, 2020

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

May 05, 2020

Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results

May 04, 2020

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2020

Akebia Therapeutics to Report First Quarter 2020 Financial Results and Discuss Recent Business Highlights

Apr 07, 2020

Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors

Apr 02, 2020

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)